Physician profile
John W Benson
NPI 1205816287
$1,311.31
in general payments reported to CMS, 2019-2025
39 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $48.20 · 2021: $190 · 2022: $241 · 2023: $224 · 2024: $239 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.92 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $76.26 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $75.25 | 2020-2024 | Shingrix, Arexvy, Bexsero |
| Kowa Pharmaceuticals America, INC. | $74.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $69.65 | 2023-2024 | Dificid, Verquvo, Belsomra |
| Abbvie INC. | $57.93 | 2022-2025 | Qulipta |
| Radius Health, INC. | $56.54 | 2021-2024 | Tymlos |
| Dexcom, INC. | $56.05 | 2019-2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $51.89 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.47 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $48.49 | 2019-2022 | |
| Lilly USA, LLC | $47.55 | 2019-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $39.86 | 2023-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $37.77 | 2021-2024 | Eohilia |
| Amarin Pharma, INC. | $32.28 | 2020-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31.43 | 2020-2022 | |
| Harmony Biosciences LLC | $30.97 | 2024 | |
| Astellas Pharma US INC | $28.90 | 2023-2025 | Myrbetriq, Veozah |
| Grifols USA, LLC | $28.08 | 2019-2023 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $27.43 | 2019-2025 | Eliquis |
| Teleflex LLC | $25.76 | 2023 | Urolift |
| Philips North America LLC | $24.85 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $23.99 | 2024 | Opsumit, Uptravi |
| Axonics, INC. | $21.41 | 2023 | Axonics |
| Medtronic, INC. | $19.23 | 2025 | Inceptiv |
| Xeris Pharmaceuticals, INC. | $18.56 | 2024 | Keveyis |
| Si-Bone, INC. | $18.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.39 | 2025 | Austedo Xr |
| Amgen INC. | $17.27 | 2024 | Repatha, Otezla |
| Allergan, INC. | $14.90 | 2019 | |
| Exact Sciences Corporation | $14.80 | 2025 | The Cologuard Plus Collection Kit |
| Viatris Specialty LLC | $13.85 | 2025 | Yupelri |
| Genentech USA, INC. | $13.55 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.24 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.01 | 2019 | |
| Biogen, INC. | $10.97 | 2019 | |
| Organon LLC | $10.68 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.